Cargando…
Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
Bone and soft tissue sarcomas account for approximately 15% of pediatric solid malignant tumors and 1% of adult solid malignant tumors. There are over 50 subtypes of sarcomas, each of which is notably heterogeneous and manifested by remarkable phenotypic and morphological variability. Anlotinib is a...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173120/ https://www.ncbi.nlm.nih.gov/pubmed/34094958 http://dx.doi.org/10.3389/fonc.2021.664853 |